Clear Health Pass Company Profile

Background

Overview

Clear Health Pass is a telehealth platform specializing in non-invasive diagnostic testing solutions, including COVID-19 and influenza A and B at-home saliva collection kits. The company is committed to providing accessible and reliable diagnostic testing that empowers individuals to take control of their health and improve health outcomes.

Mission and Vision

Clear Health Pass's mission is to save lives through next-generation diagnostics, genomics, artificial intelligence, deep learning, and global collaboration. The company envisions revolutionizing in-vitro diagnostics testing by making access to tests, understanding results, and trusting the completeness of those test results effortless for individuals.

Primary Area of Focus

The company's primary focus is on developing and providing innovative diagnostic testing solutions that are accurate, reliable, and affordable. By leveraging advanced technologies, Clear Health Pass aims to transform the healthcare industry and empower individuals to take proactive steps in managing their health.

Industry Significance

Clear Health Pass plays a significant role in the telehealth and diagnostic testing industry by offering non-invasive, at-home testing solutions. This approach addresses the growing demand for convenient and accessible healthcare services, particularly in the context of the COVID-19 pandemic and other infectious diseases.

Key Strategic Focus

Core Objectives

Innovation in Diagnostics: Developing cutting-edge diagnostic tests that are non-invasive and easy to use.

Accessibility: Ensuring that diagnostic testing is accessible to a broad population, including underserved communities.

Affordability: Providing cost-effective testing solutions to make healthcare more affordable.

Specific Areas of Specialization

Non-Invasive Testing: Specializing in saliva-based diagnostic tests for various conditions, including COVID-19 and influenza.

Telehealth Integration: Integrating diagnostic testing with telehealth services to offer comprehensive healthcare solutions.

Key Technologies Utilized

Artificial Intelligence and Deep Learning: Employing AI and deep learning algorithms to enhance the accuracy and efficiency of diagnostic tests.

Genomics: Utilizing genomic technologies to develop advanced diagnostic tests.

Primary Markets Targeted

Individual Consumers: Offering at-home testing kits for personal health monitoring.

Healthcare Providers: Supplying diagnostic tests for clinics, hospitals, and other healthcare facilities.

Public Health Organizations: Collaborating with governmental and non-governmental organizations to provide widespread testing solutions.

Financials and Funding

Funding History

As of the latest available information, Clear Health Pass has raised a total of $141.6K in funding.

Recent Funding Rounds

Specific details regarding recent funding rounds are not publicly disclosed.

Notable Investors

Information about individual investors is not publicly available.

Intended Utilization of Capital

The capital raised is intended to support the development and distribution of Clear Health Pass's diagnostic testing solutions, enhance research and development efforts, and expand the company's market presence.

Pipeline Development

Key Pipeline Candidates

COVID-19 Multi-Variant ID Lollipop Test™: A saliva-based test designed to detect multiple variants of COVID-19.

Stages of Clinical Trials or Product Development

FDA Emergency Use Authorization (EUA) Application: Clear Health Pass has submitted an EUA application to the FDA for its COVID-19 Multi-Variant ID Lollipop Test™, aiming to bring one of the most accurate tests to the market.

Target Conditions

COVID-19: Focusing on detecting multiple variants of the virus.

Influenza A and B: Developing tests for these influenza strains.

Relevant Timelines for Anticipated Milestones

FDA EUA Approval: Clear Health Pass is awaiting approval for its COVID-19 Multi-Variant ID Lollipop Test™.

Technological Platform and Innovation

Proprietary Technologies

Saliva-Based Collection Kits: Developing non-invasive, at-home saliva collection kits for diagnostic testing.

Significant Scientific Methods

Artificial Intelligence and Deep Learning: Utilizing AI and deep learning algorithms to enhance diagnostic accuracy and efficiency.

Genomic Analysis: Employing genomic technologies to develop advanced diagnostic tests.

Leadership Team

Key Executive Profiles

John Cataldi: Chief Executive Officer (CEO) of Clear Health Pass. Under his leadership, the company has focused on developing innovative diagnostic testing solutions.

Competitor Profile

Market Insights and Dynamics

The telehealth and diagnostic testing market has experienced significant growth, especially in response to the COVID-19 pandemic. Consumers are increasingly seeking convenient, at-home testing solutions, leading to a surge in demand for such services.

Competitor Analysis

HealthŌme: Offers personalized health insights through at-home testing kits.

Ocenture: Provides telehealth services with a focus on chronic disease management.

Mayo Clinic Laboratories: Offers a wide range of diagnostic testing services, including at-home collection kits.

Strategic Collaborations and Partnerships

Clear Health Pass has collaborated with Oasis Diagnostics to develop saliva-based diagnostic tests for various conditions, including COVID-19, influenza, and other diseases.

Operational Insights

Clear Health Pass differentiates itself by focusing on non-invasive, at-home diagnostic testing solutions, leveraging advanced technologies like AI and genomics to enhance test accuracy and efficiency.

Strategic Opportunities and Future Directions

The company aims to expand its product offerings to include diagnostic tests for a broader range of conditions, leveraging its technological platform to develop innovative solutions that meet the evolving needs of the healthcare market.